| abstract |
PCT No. PCT/SE92/00705 Sec. 371 Date Apr. 8, 1994 Sec. 102(e) Date Apr. 8, 1994 PCT Filed Oct. 8, 1992 PCT Pub. No. WO93/06829 PCT Pub. Date Apr. 15, 1993 <IMAGE> (I) The use of an anti-MS quinoline-3-carboxamide compound comprising the structure of formula (I), optionally with substituents for the H1-9 hydrogen, or a salt of said compound where (a) ------------- represents that there are two conjugated double bonds between atoms comprised by the dashed line (only formula I), (b) the hydrogens H7 and H8 are attached to different atoms selected from X1, X2 and the nitrogen atom in the quinoline ring, (c) X1 and X2 are independently selected from an oxygen atom or an NH9 group, said X1 and X2 being bound by a single bond to the ring when carrying H7 or H8 and by a double bond when not carrying H7 or H8, for the manufacture of a composition intended for the treatment of conditions associated with MS. Also described are treatment regimens for MS patients. The particularly preferred compound is roquinimex or a salt thereof. |